AltruBio is a startup based in Israel. Brouky records 1 investor associated with the company.
AltruBio is a biopharma company developing antibody therapeutics that target a novel regulator of the immune system to selectively remove chronically over-activated T cells implicated in autoimmune and inflammatory diseases. Its pipeline includes programs for acute graft-versus-host disease and ulcerative colitis.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.